U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29FO5
Molecular Weight 392.4619
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BETAMETHASONE

SMILES

C[C@@]1([H])C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@]2(C)[C@]1(C(=O)CO)O)O)F

InChI

InChIKey=UREBDLICKHMUKA-DVTGEIKXSA-N
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H29FO5
Molecular Weight 392.4619
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.Betamethasone is used for: treating certain conditions associated with decreased adrenal gland function. It is used to treat severe inflammation caused by certain conditions, including severe asthma, severe allergies, rheumatoid arthritis, ulcerative colitis, certain blood disorders, lupus, multiple sclerosis, and certain eye and skin conditions.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-274838400000
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-274838400000
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-274838400000
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-274838400000
Palliative
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-274838400000
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-274838400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
76.8 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
67.6 ng/mL
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
101 ng/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
796 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
811 ng × h/mL
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
46.3 μg × min/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.9 h
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
10.2 h
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
335 min
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
36%
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7.2 mg 1 times / day multiple, oral
Highest studied dose
Dose: 7.2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 7.2 mg, 1 times / day
Sources:
unhealthy, adult
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Blending science and compassion: the 30th educational symposium of the Society of Critical Care Medicine, San Francisco, USA, 10-14 February 2001.
2001
[Dyshidrosis and acral purpura during polymorphic dermatitis in pregnancy: 2 cases].
2001 Apr
Infantile periocular haemangioma treated with two days in a week betamethasone oral mini pulse therapy.
2001 Apr
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.
2001 Apr
Accelerated solvent extraction and liquid chromatography-tandem mass spectrometry quantitation of corticosteroid residues in bovine liver.
2001 Apr 5
Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required.
2001 Aug
Multiple courses of antenatal betamethasone and cognitive development of mice offspring.
2001 Aug
Evaluation of the inhibitory activity of topical indomethacin, betamethasone valerate and emollients on UVL-induced inflammation by means of non-invasive measurements of the skin elasticity.
2001 Aug
Bias shown in study of better care for patients with skin disease?
2001 Feb
Repeated fetal betamethasone treatment and birth weight and head circumference.
2001 Feb
Effect of antenatal betamethasone treatment on microtubule-associated proteins MAP1B and MAP2 in fetal sheep.
2001 Feb 1
Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp.
2001 Jan
[Early cardiovascular effects of corticotherapy for bronchopulmonary dysplasia].
2001 Jan
Two cases of severe bronchopneumonia due to influenza A (H3N2) virus: detection of influenza virus gene using reverse transcription polymerase chain reaction.
2001 Jan
The effect of multidose antenatal betamethasone on maternal and infant outcomes.
2001 Jan
Surfactant levels after reversible tracheal occlusion and prenatal steroids in experimental diaphragmatic hernia.
2001 Jan
The interactive effects of endotoxin with prenatal glucocorticoids on short-term lung function in sheep.
2001 Jul
An evidence-based assessment of occlusal adjustment as a treatment for temporomandibular disorders.
2001 Jul
Repeated prenatal corticosteroid administration delays myelination of the corpus callosum in fetal sheep.
2001 Jul
Inflammatory pathological changes in a 2-year-old boy with Charcot-Marie-Tooth disease.
2001 Jul
Deleterious effects of local corticosteroid injections on the Achilles tendon of rats.
2001 Jun
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids).
2001 Jun
Treatment of de Quervain's disease:role of conservative management.
2001 Jun
Non-linear changes of electrocortical activity after antenatal betamethasone treatment in fetal sheep.
2001 Mar 1
Lung morphometry after repetitive antenatal glucocorticoid treatment in preterm sheep.
2001 May
High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas.
2001 May
Multiple courses of antenatal steroids: risks and benefits.
2001 Sep
Fetal monkey surfactants after intra-amniotic or maternal administration of betamethasone and thyroid hormone.
2001 Sep
Programming effects in sheep of prenatal growth restriction and glucocorticoid exposure.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Can also be used topically https://medlineplus.gov/druginfo/meds/a682799.html
The initial dosage of parenterally administered Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may vary from 0.25 to 9 mg per day depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of betamethasone for a week followed by 12 mg every other day for 1 month are recommended.In pediatric patients, the initial dose of betamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2bsa/day).
Route of Administration: Parenteral
In Vitro Use Guide
Betamethasone (10(-6)M) significantly reduced both pH 6-induced bronchial response and CGRP-like immunoreactivity overflow in guinea-pig isolated perfused lung.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:16:35 UTC 2021
Edited
by admin
on Fri Jun 25 21:16:35 UTC 2021
Record UNII
9842X06Q6M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BETAMETHASONE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
DEXAMETHASONE SPECIFIED IMPURITY B [EP]
Common Name English
VISUBETA
Code English
FLOSTERON
Common Name English
BETAMETHASONE [WHO-DD]
Common Name English
BETAMETHASONE [VANDF]
Common Name English
FLUBENISOLONE
Common Name English
BETAMETHASONE [JAN]
Common Name English
BETAMETHASONE ACETATE IMPURITY A [EP]
Common Name English
DEXAMETHASONE IMPURITY B [EP]
Common Name English
SCH-4831
Code English
BETAMETHASONE DIPROPIONATE IMPURITY A
Common Name English
BETAMETHASONE [EP]
Common Name English
RINDERON
Brand Name English
BETAMETHASONUM [WHO-IP LATIN]
Common Name English
SCH 4831
Code English
BETAMETHASONE [WHO-IP]
Common Name English
BETAMETHASONE [MART.]
Common Name English
CELESTONE
Brand Name English
BETAMETHASONE [MI]
Common Name English
BETAMETHASONE [USP-RS]
Common Name English
BETAMETHASONE [USAN]
Common Name English
NSC-39470
Code English
DESACORT-BETA
Common Name English
BETAMETHASONE [INN]
Common Name English
CELESTENE
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17,21-TRIHYDROXY-16-METHYL-, (11.BETA.,16.BETA.)-
Systematic Name English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE.
Systematic Name English
BETAMETHASONE [USP]
Common Name English
BETAMETHASONE [EP MONOGRAPH]
Common Name English
BETAMETHASONE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
WHO-VATC QS03BA03
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
CFR 21 CFR 524.1044D
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
CFR 21 CFR 524.1044I
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC R03BA04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
CFR 21 CFR 524.1044B
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QA07EA04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC D07AC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
FDA ORPHAN DRUG 492415
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QD07BC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC D07CC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC S01BB04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QD07CC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QR03BA04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC S01CA05
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QS02CA90
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC S01CB04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC A07EA04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 13.3
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QS01BA06
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC H02AB01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC S01BA06
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
CFR 21 CFR 524.1044G
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QD07XC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QS01CB04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QH02AB01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
CFR 21 CFR 524.1044F
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC R01AD06
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC D07XC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QC05AA05
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC S02BA07
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QS03CA06
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC D07BC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
LIVERTOX 100
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QS01BB04
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC S03CA06
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC S03BA03
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QD07AC01
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QS01CA05
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-ATC C05AA05
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QR01AD06
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
WHO-VATC QS02BA07
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
Code System Code Type Description
RXCUI
1514
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M2452
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY Merck Index
USP_CATALOG
1066009
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY USP-RS
MESH
D001623
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
LACTMED
Betamethasone
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
ChEMBL
CHEMBL632
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
EVMPD
SUB05797MIG
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
NCI_THESAURUS
C303
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
BETAMETHASONE
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY Description: A white or creamy white powder; odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS. Category: Adrenoglucocorticoid. Storage: Betamethasone should be kept in a tightly closed container, protected from light. Definition: Betamethasone contains not less than 96.0% and not more than 104.0% of C22H29FO5 calculated with reference to the dried substance.
WIKIPEDIA
BETAMETHASONE
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
EPA CompTox
378-44-9
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
HSDB
3015
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
PUBCHEM
9782
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
INN
1045
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
LACTMED
Betamethasone, Topical
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
CAS
378-44-9
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
FDA UNII
9842X06Q6M
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
DRUG BANK
DB00443
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-825-4
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
DRUG CENTRAL
348
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
IUPHAR
7061
Created by admin on Fri Jun 25 21:16:36 UTC 2021 , Edited by admin on Fri Jun 25 21:16:36 UTC 2021
PRIMARY
Related Record Type Details
DEGRADENT -> PARENT
DEGRADENT -> PARENT
DEGRADENT -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (UV)
EP
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.56.pdf
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC